TY - JOUR
T1 - Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients
AU - Cairo, M. S.
AU - Tarek, N.
AU - Lee, D. A.
AU - Delaney, C.
N1 - Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Cord blood (CB) transplantation is an alternate source of human hematopoietic progenitor cells for allogeneic stem cell transplantation in children and adolescents with both malignant and nonmalignant diseases. Current limitations included delay in hematopoietic reconstitution, increased incidence of primary graft failure and slow cellular immunoreconstitution. These limitations lead to a significant increase in primary graft failure, infectious complications and increased transplant-related mortality. There is a number of experimental approaches currently under investigation including cellular engineering to circumvent these limitations. In this review, we summarize the recent findings of utilizing ex vivo CB expansion with Notch1 ligand Delta 1, mesenchymal progenitor cells, the use of human placenta-derived stem cells and CB-derived natural killer cells. Early and preliminary results suggest some of these experimental cellular strategies may in part ameliorate the incidence of primary graft failure, delays in hematopoietic reconstitution and/or slowness in cellular immune reconstitution following unrelated CB transplantation.
AB - Cord blood (CB) transplantation is an alternate source of human hematopoietic progenitor cells for allogeneic stem cell transplantation in children and adolescents with both malignant and nonmalignant diseases. Current limitations included delay in hematopoietic reconstitution, increased incidence of primary graft failure and slow cellular immunoreconstitution. These limitations lead to a significant increase in primary graft failure, infectious complications and increased transplant-related mortality. There is a number of experimental approaches currently under investigation including cellular engineering to circumvent these limitations. In this review, we summarize the recent findings of utilizing ex vivo CB expansion with Notch1 ligand Delta 1, mesenchymal progenitor cells, the use of human placenta-derived stem cells and CB-derived natural killer cells. Early and preliminary results suggest some of these experimental cellular strategies may in part ameliorate the incidence of primary graft failure, delays in hematopoietic reconstitution and/or slowness in cellular immune reconstitution following unrelated CB transplantation.
UR - http://www.scopus.com/inward/record.url?scp=84953368390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953368390&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.196
DO - 10.1038/bmt.2015.196
M3 - Review article
C2 - 26367220
AN - SCOPUS:84953368390
SN - 0268-3369
VL - 51
SP - 27
EP - 33
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 1
ER -